Top ▲

Multicentric Castleman disease

Disease ID:1233
Name:Multicentric Castleman disease
Associated with:0 target
1 immuno-relevant ligand
Multicentric giant lymph node hyperplasia
MCD is an aggressive form of Castleman disease (a benign lymphoproliferative disorder) that mainly results from human herpesvirus 8 (HHV8) infection. MCD affects multiple sets of lymph nodes and other tissues throughout the body. Symptoms include fever, diffuse lymphadenopathy, hepatosplenomegaly, involvement of the respiratory system and increased C-reactive protein.
Database Links
OMIM: 148000
Orphanet: ORPHA93686


No target related data available for Multicentric Castleman disease


Key to terms and symbols Click ligand name to view ligand summary Click column headers to sort
Ligand References Clinical and Disease comments
Immuno Disease Comments: Approved therapeutic for MCD.
Clinical Use: Approved to treat multicentric Castleman's disease (MCD, a.k.a. giant lymph node hyperplasia), a rare blood disorder.

SARS-CoV-2 and COVID-19: Siltuximab is being investigated as a mechanism to combat cytokine storm resulting from an exaggerated response of the immune system in patients with severe COVID-19. | View clinical data